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B L O O D  C O M P O N E N T S
Costs and benefits of bacterial culturing and pathogen reduction 
in the Netherlands
Mart P. Janssen, Cees L. van der Poel, Erik Buskens, Luc Bonneux, Gouke J. Bonsel, and Ben A. van Hout
BACKGROUND: Bacterial contamination is a life-
threatening risk of blood transfusion, especially with 
platelet (PLT) transfusions. Bacterial culturing (BCU) of 
PLTs as well as pathogen reduction (PRT) reduce the 
likelihood of such contamination. The cost-effectiveness 
(CE) of these interventions was analyzed after the 
introduction of the diversion pouch during blood 
collection.
STUDY DESIGN AND METHODS: The balance 
between costs and benefits of preventing adverse events 
due to PLT transfusion was assessed with a mathematical 
decision model and Monte Carlo simulations. Model 
parameters were obtained from the literature and from 
Dutch Sanquin blood banks. The balance between costs 
and benefits is assessed in terms of costs per quality-
adjusted life-year (QALY).
RESULTS: The costs per 100,000 PLT concentrates in 
the Netherlands are estimated at $3,277,032 
(€2,520,794) for BCU and at $18,582,844 (€14,294,495) 
for PRT. In comparison to the situation without BCU and 
PRT, costs per QALY are estimated at $90,697 (€69,767) 
for BCU (95% confidence interval [CI], $18,149-
$2,088,854) and at $496,674 (€382,057) for PRT (95% 
CI, $143,950-$8,171,133). The ratio of differences in 
costs and QALYs between BCU and PRT (the relative 
CE) is estimated at $3,596,256 (€2,766,351; 95% CI, 
$1,100,630-$24,756,615). Large uncertainty in sepsis 
complication rates and PLT recipient survival exist, 
causing large uncertainties in the absolute CE for both 
interventions.
CONCLUSIONS: As a result of the unknown probability 
of sepsis complications and PLT recipient survival, the CE 
ratios of BCU and PRT in the Dutch setting are highly 
uncertain. Despite these large uncertainties, it can be 
concluded that BCU is without doubt more cost-effective 
than PRT.
ith the progression of technologies, the
risks of blood transfusions have been
reduced considerably over the past few
decades.1 In the 1980s the risk of viral
infection by blood transfusion exceeded 1 in a 1000 trans-
fusions; nowadays this risk is more than a thousand times
lower.2 For labile blood products, the focus of prevention
for viral transmission was on blood screening techniques.
This approach was highly successful, but leaves residual
risks that are presently primarily determined by bacterial
sepsis acquired through contaminated platelets (PLTs).2-4
Several techniques are available to prevent bacterial con-
tamination from blood products, in particular the use of
a diversion pouch, bacterial culturing (BCU) and patho-
gen reduction (PRT).5-7 In November 2001, BCU on
100 percent of PLT concentrates was introduced in the
Netherlands. With BCU, aerobic and anaerobic samples of
the finished pooled PLT product are kept at 35°C in
coculture with storage of the buffy coat–derived PLT
pools, and bacterial contamination is detected through
measurement of CO2.5,8 In July 2004 this approach was
supplemented by the introduction of a diversion pouch at
blood collection. This allows separation of the first 20 to
30 mL of blood, which is most likely to be contaminated
by skin flora.6
W
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Another approach for reducing bacterial risk of PLTs
transfusion is PRT, which recently became available for
treatment of PLT products.7 The most developed method
for photochemical inactivation of bacteria is achieved by
addition of a synthetic psoralen and illumination with
UVA light.9,10 This method is considerably more expensive
than BCU but offers the additional benefit of reducing
viral residual risks. The Dutch Health Council recently
advised awaiting the results of more clinical studies, in
particular on the added safety in an already safe system of
blood provision, before the introduction of PRT.11
The Dutch Health Authorities have raised the issue of
optimal versus maximal blood safety. With PRT likely to be
more effective but also more costly, it may well be that—
even when PRT would have maximum benefits—the bal-
ance between costs and benefits would still be unaccept-
able when considering the current Dutch situation with
the diversion pouch. This idea is analyzed in this study,
and in doing so we also assess the cost-effectiveness (CE)
of the introduction of BCU: a decision that has been taken
previously without an extensive evaluation of costs and
benefits.
MATERIALS AND METHODS
The analysis concerns the comparison of two interven-
tions reducing the risk of contaminated PLT transfusions
(BCU and PRT) in a setting where the diversion pouch is
part of standard practice and neither BCU nor PRT are
introduced. We employ BCU data of 2 years of screening
in the Netherlands with a diversion pouch to assess the
frequency of bacterial contamination and the sensitivity
of BCU. Costs and benefits are analyzed using a mathe-
matical model that brings together data on the probability
of blood contamination by bacteria and the main blood
transmissible viruses: data on the consequences of con-
tamination and data on the costs of the interventions. The
analysis is performed from a direct cost perspective,
which means that only the direct costs required for med-
ical treatment are considered. There are three separate
situations that are analyzed: (1) the baseline situation
with diversion pouch, (2) the situation where BCU on
100 percent of the PLT products is being applied next to
the use of a diversion pouch, and (3) where a PRT tech-
nique is applied next to the use of a diversion pouch. The
CE of the last two alternatives is compared to the baseline
situation and to each other. The latter relative CE of PRT
to BCU is expressed in the ratio of differences in costs and
differences in quality-adjusted life-years (QALYs) between
BCU and PRT.
CE
The estimates of costs are limited to the costs of the risk
reduction techniques and the direct medical costs associ-
ated with the consequences of infections. The same infec-
tions are associated with estimates of life-years lost and
quality of life lost, expressed in terms of QALYs.12 CE is
expressed in terms of costs per QALY. Future costs and
effects are discounted with a discount rate of 4 percent in
accordance with guidelines for CE analyses.13 Results are
expressed in terms of point estimates assuming 100,000
PLT transfusions per year.
The WHO recently reported that each life-year is val-
ued at around three times the annual earnings.14 There-
fore, an indication for a CE threshold would be three times
the gross domestic product per head. For the Netherlands
the threshold would be $110,000 per QALY and is compa-
rable to the value for the United States ($120,000).
Uncertainties are addressed by uni- and multivariate
sensitivity analyses. The results of the multivariate sensi-
tivity analyses are used to calculate uncertainty margins
surrounding the outcomes.
Contamination probabilities
A critical variable of the CE model is the probability of
contamination. The estimated probability of an infectious
PLT transfusion for viruses can be derived from the mea-
sured donor incidence rates and a virus specific window
period.15 Table 1 shows the estimated residual risk of viral
contamination per PLT product for human immunodefi-
ciency virus (HIV), hepatitis C virus (HCV), hepatitis B
virus (HBV), and human T-lymphotropic virus-1 and -2
(HTLV-1 and -2) in the Netherlands.16
Hepatitis B viremia and antigen are often only tran-
siently present in the donor blood, which leads to under-
estimation of the actual incidence rate. A method for
estimating a correction factor for the measured incidence
rate based on donation intervals is described in the liter-
ature.17,18 On the basis of donation intervals from the San-
quin blood banks, the incidence rate was estimated to be
a factor 3.0 higher than the recorded incidence rate. “PLT
concentrates” in the Netherlands are prepared according
to the buffy-coat method from five whole-blood dona-
tions. It should be noted that in the Netherlands only
repeat donations are used for the preparation of blood
products.
Since November 2001, in the Netherlands the actual
bacterial contamination in PLT concentrates has been
measured in 100 percent of the products. In July 2004, a
diversion pouch at blood collection was also introduced.
The diversion pouch separates the first 20 to 30 mL of all
donations, which are most likely to be contaminated by
skin flora. The risk of bacterial contamination of PLT con-
centrates—as presented in Table 1—is based on these
measures selecting the results of 111,111 tested PLT prod-
ucts, collected after the introduction of the diversion
pouch. As point estimate, we used a rate of 0.42 percent
with an uncertainty margin of 0.32 to 0.56 percent.20
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Over the years 1998 to 2001 the Sanquin Blood Supply
Foundation received on average reports of one HBV infec-
tion and five complications from bacterial contamination
per year resulting from hemovigilance reported by Dutch
hospitals. Because underreporting is likely, the reported
incidents in combination with the annual number of PLT
transfusions in the Netherlands (50,000) are used to esti-
mate the lower bounds of the complication rates used in
our model.
Consequences of contaminated donor blood
Complications of transfusion can arise immediately after
the transfusion, in the case of a bacterial contamination,
or at a later stage, in the case of a transmission of a chronic
viral infection. A bacterial contamination becomes clini-
cally apparent as sepsis. Although the literature offers var-
ious estimates of the incidence of sepsis, no reliable data
are available on the likelihood of sepsis after transfusion
of contaminated PLTs.2,21-26 Only recently an was article
published where an estimate was given for the probability
of sepsis from contaminated PLT transfusions ranges from
1 in 10 to 2 in 5 (10-40%).27 We used a point estimate of
10 percent and applied a wide margin of 1 to 40 percent to
express the uncertainty surrounding this estimate. The
lower limit of 1 percent represents the probability at which
the model predicts the five cases of sepsis as reported by
hemovigilance in the past. The upper limit (40%) equals
the upper limit from the range estimate for the probability
of sepsis from contaminated PLT transfusions but also
corresponds to the percentage of contaminated trans-
fused pooled PLTs that did not cause clinical complica-
tions in clinical practice (44%).8,27 The uncertainty of the
estimation was modeled with a Weibull distribution.28
When considering bacterial sepsis, the literature reports a
total of 22 deaths in 118 cases, resulting in a case-fatality
rate of 19 percent.23-26 We applied a beta distribution based
on these figures to express its uncertainty.28
The consequences of transmitted viral infections are
difficult to estimate because most viral infections have a
variable, host-dependent prognosis. Several articles dealt
with this issue by models on transmitted chronic viral
infections.29-35 In our model we made the conservative
assumption that viral contamination will lead to transmis-
sion, cause disease, and bring about associated costs and
loss of health. Even though this is a worst-case scenario, it
is in line with the thought that we assess maximum ben-
efits from PRT.
Effectiveness of interventions considered
Validation tests of the BCU system indicated a high sensi-
tivity, defined as the proportion of contaminated products
that are actually identified as being contaminated.36,37 Its
use in a production environment under a wide spectrum
of bacterial contaminations might show less favorable
results, as was illustrated by recent experience from rou-
tine practice in the Netherlands.8 In routine practice
56 percent of 184 contaminated PLT products (mainly
diphtheroid rods) were found to be transfused before
detection by the culturing system. Even though none of
these products led to complications, two nondetected
contaminated PLT products led to severe septic incidents.8
The rate of nondetected contamination of PLTs resulting
in sepsis events is therefore 1 percent. Because the actual
amount of unobserved contaminated PLTs is unknown
and only those detected through the hemovigilance
system are accounted for, in our model we allowed for a
factor of 10 for underreporting of septic incidents or
detection of contaminated products. We therefore mod-
eled a sensitivity of the BCU system of 90 percent, with an
uncertainty range of 9 percent.
PRT has demonstrated the reduction of contamina-
tion with at least a log 4 factor for a wide range of bacteria,
viruses, and parasites.7 PRT, however, has shown to fail
reduction of bacteria in PLT concentrates as well.38 Corre-
sponding with the idea that we will analyze the CE of PRT
at its best, we presumed the sensitivity of PRT to be
100 percent, an extreme assumption in favor of the PRT
treatment.
TABLE 1. Contamination risks of PLT blood products














(E = B × D)
Probability of 
infected pooled (n = 5)
PLT transfusion 
in the Netherlands 
(per million) (F = 5 × E)
HIV viral infection 5.5 11 0.03 0.2 0.8
HBV viral infection* 32 (11) 59 0.16 5 26
HCV viral Infection 2.6 10 0.03 0.1 0.4
HTLV-I/II viral Infection 1.5 51 0.14 0.2 1.0
Bacterial contamination of PLTs 3700
* Adjusted for nondetection. (The actual measured incidence rate is given in parentheses.)
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Costs and effects
The cost estimates per PLT concentrate for BCU and PRT
are presented in Table 2. Costs associated with BCU have
been derived from operational data of the Sanquin blood
banks. The operational costs for PRT were estimated by
Sanquin and were based on the price as indicated by the
manufacturer ($100 per pooled PLT concentrate; all costs
were converted at a rate of 1.3 US$ per Euro). The cost of
personnel, housing, and maintenance for PRT production
are estimated at $19 per product. In addition, the cost of
production loss due to the limited shelf life (19.8% at 5
days’ outdating,39 which is current practice), the produc-
tion loss caused by the PRT process itself (10%), and the
increased PLT usage in clinical practice (ranging from 0 to
30%) was accounted for.10,40 All costs reflect costs in the
year 2002.
On the basis of national hospital records the mean
costs of sepsis incidents have been calculated to be $7000
per incident.41 An estimate of the upper limit to the cost
of sepsis of $18,000 was derived considering all costs of all
events where sepsis was diagnosed. Based on these fig-
ures, we estimate the direct costs of sepsis treatment at
$12,500 with an uncertainty margin of $7000 to $18,000.
The costs of treatment of viral diseases require longer
time horizons and depend on patient prognosis. In a
recent publication, estimates of the annual cost of viral
diseases ranged from $1,000 to $50,000 per year depend-
ing on the type of infection.33 An earlier CE study on PLT
use indicated a maximum discounted cumulative lifetime
cost of $150,000 (1996 US dollars).31 Given the annual fig-
ures, this might seem low, but periods of high costs are
accompanied with high mortality rates. These costs are
also likely to occur in the remote future where discounting
leads to lower values.
In our model we made the assumption that the dis-
counted total lifetime cost of a viral infection would be
$250,000, irrespective of the type of viral disease transmit-
ted and age of the infected patient. We used a range of
$125,000 to $375,000 to express our uncertainties.
In the Netherlands, PLT recipients are on average
50 years of age.42 Patient survival is paramount in deter-
mining the CE, especially when the life expectancy is low
as is the case with PLT recipients. The literature indicates
that the 5-year survival of PLTs is only 21 percent.43 We
calculated the life expectancy of PLT recipients on basis of
the results from Wallis and coworkers42-44 and extended the
life expectancy on the basis of our national health statis-
tics and in accordance with the age distribution on the
Dutch PLT recipient distribution. Data from the EuroQol
group indicate that the average 50-year-old person has a
quality-of-life index of approximately 0.75, decreasing to
a value of approximately 0.65 at the age of 85.45 Using these
figures, the expected discounted number of QALYs of a
Dutch PLT recipient is estimated at 4.4 years, ranging
between 2 and 6 years. This estimate is used for the num-
ber of life-years lost in case a patient obtains an infection
and dies from sepsis.
From other CE studies it was derived that the reduc-
tion of cumulative QALY due to viral infections is less than
5 percent.31,33 Therefore we presumed the utility of patient
obtaining a viral infection to be 95 percent (ranging
between 90 and 100%).
Sensitivity analysis
On the basis of the assumptions as outlined above, event
trees were constructed describing incidents and out-
comes after blood transfusion for both treatment alterna-
tives and the reference situation (no additional
TABLE 2. Model and range parameters
Description
Parameter 
value Range Distribution type
Median recipient age (years)  50  0-90 Dutch PLT
Mean QALYs  4  2-6 recipient
Probability of bacterial contamination (%)  0.42 0.32-0.56 Beta
Probability of severe sepsis given bacterial contamination (%)  10  1-40 Weibull
Probability of death given severe sepsis (%)  19  13-27 Beta
Sensitivity (%)
BCU  90  81-99 Pert
PRT  100
Probability of viral infection (all infections)  3 × 10−5 1 × 10-6-6 × 10−5 Beta
Cost of sepsis treatment ($) 12,500 7,000-18,000 Pert
Workup cost ($)
BCU  31  28-35 Pert
PRT  178  152-205 Pert
Increased usage of PRT PLTs (%)  15  0-30 Uniform
Total discounted cost of treatment of patient with viral infection ($) 250,000 125,000-375,000 Pert
Utility of patient with viral infection  0.95 0.9-1.0 Pert
Discount rate (%)  4
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treatment). Additionally, uni- and multivariate sensitivity
analyses were carried out to assess the robustness of the
results. The univariate sensitivity shows to what extent the
estimates of costs per QALY change when the underlying
estimates are subsequently changed within the margins of
uncertainty. We analyzed whether one might draw differ-
ent conclusions when varying them within these margins.
In the multivariate sensitivity analysis costs and effects are
assessed when all estimates are varied at the same time
drawing at random from the distributions reflecting the
uncertainties (Monte Carlo simulation). Table 2 summa-
rizes all point estimates, the associated uncertainty mar-
gins, and the distributions used in the sensitivity analyses.
In the case of normal distributions, the lower and upper
limits of the uncertainty margins correspond with the
lower and upper 95 percent limits. In the case of Pert dis-
tributions, the lower and upper limits are the real lower
and upper limits. A Pert distribution is a truncated beta
distribution that is characterized by a lower limit, an
upper limit, and a most likely value.28 When the distances
between the most likely value and the upper and lower
limit are identical (as is the case here) the shape resembles
that of a normal distribution with truncated upper and
lower bounds.
RESULTS
Three scenarios are analyzed after the introduction of the
diversion pouch: (1) no additional treatment, (2) BCU, and
(3) PRT. Figure 1 shows the event tree for
the reference situation (without addi-
tional treatment) and its associated out-
come probabilities together with the
main outcomes of all three scenarios.
It is estimated that in 100,000 PLT
transfusions BCU reduces the number
of adverse events (clinical sepsis or
transmission of viral diseases) from 45
to 7. In the case of perfect protection by
PRT, this number would reduce it to 0.
The additional costs of BCU are esti-
mated at $3,277,032; the additional cost
of PRT, at $18,582,844. This means that
the cost of BCU and PRT equal $86,079
and $411,850, respectively, per event
prevented. When comparing PRT with
BCU, it is estimated that PRT will pre-
vent an additional three sepsis events,
one sepsis death, and three viral infec-
tions leading to a cost per additional
prevented event of $2,170,959.
When associating the costs per
event prevented with estimates of the
QALYs lost due to these events, esti-
mates are obtained of the cost per QALY
gained. Figure 2A shows the results in terms of the relative
CE of both treatments as compared to the “no additional
treatment” alternative. In this graph on the vertical axis
the difference in costs are plotted against the difference in
QALYs on the horizontal axis. The upper cloud of points
represents the outcomes of 1000 random draws from the
multivariate sensitivity analysis regarding the comparison
between PRT and no additional treatment. The lower
cloud represents these when comparing BCU with no
additional treatment. The central estimates are that BCU
gains 31 (95% confidence interval [CI], 2-103) QALYs
against a net cost of $2,801,202 (95% CI, $1,731,058-
$3,343,982) and that PRT gains 35 (95% CI, 2-114) QALYs
against a net cost of $17,349,086 (95% CI, $14,447,548-
$20,420,219). For each of the situations, point estimates
and 95 percent CIs are drawn in the figure. Also the CE
threshold value is shown.
The costs per QALY are estimated at $90,697 (95% CI,
$18,149-$2,088,854) for BCU and at $496,674 (95% CI,
$143.950-$8.171.133) for PRT. Figure 2B shows the results
when comparing PRT with BCU. Here differences in cost
between PRT and BCU are plotted against differences in
QALYs, with the same data as shown in Fig. 2A. The central
estimate is a cost per QALY of $3,596,256 (95% CI,
$1,100,630-$24,756,615).
In Table 3 the outcomes of the univariate sensitivity
analysis are given, where it is analyzed to what extent the
CE ratios of BCU versus no additional treatment and PRT
versus BCU change when changing the subsequent point
Fig. 1. Event tree model, outcome frequencies, and costs per treatment option per 
100,000 PLT transfusions.
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estimates to the upper and lower limits of their uncer-
tainty ranges (see also Fig. 3). Table 3 and Fig. 3 show that
the main parameters affecting the CE are the probability
of sepsis given bacterial contamination, the patients’
quality-adjusted life expectancy, the probability of death
given sepsis, and the probability of bacterial contamina-
tion. The model outcome is relatively insensitive to
changes in all other model parameters. The table also
shows that the relative CE of PRT to BCU is most sensitive
to the probability of sepsis given bacterial contamination
and the test sensitivity of the BCU system.
DISCUSSION
The results from this study lead to the
conclusion that in the Netherlands the
CE of BCU is superior to PRT. The main
reason is the fact that BCU significantly
reduces the incidence of sepsis events,
which is the major contributor to the
overall risk of PLT transfusions. Moreover,
it does so against relative low costs.
Although PRT may reduce this probabil-
ity even further, the increase in costs are
well above the costs that are considered
acceptable.14
The main uncertainties with respect
to the absolute CE concern the probabil-
ity of bacterial contamination–related
complications and the expected health
gain. These uncertainties, however, affect
both treatment options equally. So even
though the absolute CE of BCU can be
questioned (there is a 53% chance that it
will be above the CE threshold), it will by
far be more cost-effective than PRT as is
shown by the relative CE graph shown in
Fig. 2B. As awareness of bacterial con-
tamination of PLTs increases and hemov-
igilance systems generate more data,
more knowledge about the sepsis proba-
bility will become available, which will
enable better estimates for the CE of
these safety measures.
The modeled probabilities of sepsis
(see Fig. 1; 34 + 8 = 42 per 100,000
transfusions) and death (8 per 100,000
transfusions) through bacterial contami-
nation are in line with values reported in
literature (40-100 and 7-13 per 100,000
for sepsis and death, respectively).24,46 It
should be noted that the modeled values
reflect the incidence rates after the intro-
duction of the diversion pouch in the
Netherlands, where the contamination
and incident probability would be
expected to be a factor two lower than the published inci-
dence rates.20,47 Possible other causes for differences in
incidence rates might be: (1) geographic and demographic
differences, (2) differences in donor collection procedures
(e.g., arm cleansing), (3) the fact that the estimated sepsis
probability does not reflect the Dutch setting, or (4) the
reported sepsis and death incidence rates underestimate
true incidence rates.
The number of sepsis events after introduction of the
BCU system as predicted by the model is 1 in 24,000 trans-
fusions. The number of sepsis events reported after the
Fig. 2. (A) Relative CE of BCU and PRT versus “no additional treatment.” (B) Relative 
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introduction of the BCU system, but before the introduc-
tion of the diversion pouch, was 1 in 14,000.8 Therefore the
projected number of sepsis events is about half the num-
ber of events found before the introduction of the diver-
sion pouch and corresponds to the expected number of
cases.
As a result of a high bacterial contamination proba-
bility (0.42%), there is a high number of sepsis events pre-
dicted by our model. There is a fairly large discrepancy
between the number of estimated sepsis events from
Fig. 1 (42 per year) and the number of sepsis events as
reported by hemovigilance (5 per year). The hemovigi-
lance reporting is likely to underesti-
mate the true number of sepsis events
because patients requiring PLT transfu-
sions are generally severely ill and have
sepsis from many other causes. Data
from our academic hospital show that
10 percent of nondischarged PLT recipi-
ents will not survive one week past the
date of transfusion. Even if the actual
sepsis probability would be much lower
than the sepsis probability modeled,
however, this would result in a higher
estimate for the CE ratio, but will not
affect the relative CE of BCU over PRT
as it will affect the benefits for both
interventions.
The experience with the BacT/
ALERT system in a “release as negative
to date” schedule has shown that a large
number of contaminated pooled PLTs
(56%) are transfused before detection.8
This shows that the system of BCU is not
at all flawless. Contamination detected
after delivery to the hospital, however,
concerns bacteria that are slow growing
and generally less pathogenic. Appar-
ently, these do not lead to complications and the system
seems to be adequately safeguarding transmission of bac-
terial contamination. Even though in some cases the sys-
tem does fail, as shown by the cases reported back through
the hemovigilance system, it remains by far a more cost-
effective than PRT in preventing transmission of bacterial
contamination through PLT products.
Table 3 and Fig. 3 clearly illustrate the effect of the
high uncertainty with respect to the likelihood of sepsis
complications on the CE of both BCU and PRT. Our anal-
ysis shows that as long as the probability of sepsis exceeds
1 in 2800 transfusions, the CE of BCU is expected to be





















Probability of sepsis given bacterial contamination (%)  1-40 925 −88 703 −77 306 −72
Mean discounted quality adjusted life expectancy (years)  2-6 118 −27 118 −27 118 −27
Probability of death given severe sepsis (%)  13-27 47 −30 46 −30 38 −27
Probability of bacterial contamination (%) 0.31-0.56 38 −29 33 −25 27 −22
Workup cost PRT ($)  152-205 0 0 −16 16 −19 19
Sensitivity BCU (%)  81-99 13 −11 0 0 −43 324
Workup cost BCU ($)  28-35 −12 12 0 0 2 −2
Cost of sepsis treatment ($) 7,000-18,000 7 −7 1 −1 0 0
Probability of viral infection (all infections) 1 × 10−6-6 × 10−5 0 0 5 −6 20 −19
Total discounted viral infection treatment cost ($) 125,000-375,000 0 0 2 −2 2 −2
Utility of patient with viral infection (QALY) 0.9-1.0 0 0 −2 2 −13 18
Fig. 3. Univariate sensitivity analysis of PRT and BCU. For each model parameter the 
CE range given in Table 2 is indicated with a line. The line markers indicate the out-
comes calculated for the actual upper and lower range values. The base-case CE esti-
mates are found in the centers of the two graph clusters. Higher complication 
probabilities will cause preventative measures to be more cost-effective and move the 
model outcome towards the cost-effective side of the graph (bottom right-hand side). 
This is also true in case there is much to be gained from prevention: thus for high 








0 50 100 150 200





























high probability / 
high life expectancy 
low probability /
low life expectancy
BACTERIAL CULTURE AND PATHOGEN REDUCTION
Volume 46, June 2006 TRANSFUSION 963
below the $110,000 per QALY threshold. Contrarily, there
is not one variable which—within its margins of uncer-
tainty—would lead to an estimate of the costs per QALY of
PRT under $110,000 or under $1,000,000 if compared to
BCU. As such, the conclusion that PRT is not very cost-
effective in comparison to BCU can be called robust. The
reason is that whatever assumption is made, there is little
doubt that BCU is a major step forward in comparison to
no additional treatment. After BCU, which reduces
90 percent or more of the bacterial contamination risk,
there is barely any residual risk left. Even though PRT
reduces risk completely (in our theoretical model that is),
the additional effectiveness of PRT is relatively small in
comparison to the additional costs.
Table 3 also shows that the relative CE is primarily
influenced by the probability of sepsis given bacterial con-
tamination and the sensitivity of BCU. This is caused by
the fact that by reducing this probability the relative gain
from PRT will diminish and as a result, the CE ratio will
increase. An increase of the sensitivity of BCU will directly
cause an increase of the relative CE ratio.
Bell and colleagues33 estimated the CE of PRT for PLT
products. Here the baseline analysis showed a CE ratio of
PRT in the order of $500,000 to $2,000,000 per QALY
depending on the patient type.33 This is well in line with
our point estimate of $496,674 and a 95 percent CI
($143,950-$8,171,133). In contrast to this study, we did not
model any potential future scenarios. For example, long-
term toxic side effects of PRT as a result of treatment were
not considered, but might influence the acceptability this
technology. We also did not model any effects of an
unknown hepatitis C virus like agent, nor did we model
any effects of an unknown nonenveloped virus that is rel-
atively unaffected by PRT.
In our analysis we did not consider the irradiation
procedure for immunosuppressed patients. We did not
consider this specific subgroup as they only consume
15 percent of all PLT concentrates in the Netherlands.
Possible protection against cytomegalovirus was also
not assessed as 100 percent of PLTs are leukodepleted
to a level less than 106 cells per product. The Cana-
dian CMV consensus concluded that leukodepletion
reduces CMV risk by transfusion to an undetectable
level.48
The costs and effects associated with viral infections
in our model could be considered crude or overly simplis-
tic, especially as advanced models exist that describe dis-
ease progressions and associated costs for these diseases
in detail. We applied uncertain but conservative esti-
mates for both costs and effects, however, with respect to
these diseases and found that these assumptions do not
at all affect the outcome of the CE comparison of BCU
and PRT, as is shown in the sensitivity analysis. Therefore,
the model used is sufficiently adequate to serve its
purpose.
One additional beneficial effect of BCU that is not
included in our analyses is the shelf-life extension of bac-
terially screened PLTs. It has been shown that with BCU
the PLT shelf life can be extended from 5 to 7 days, which
will cause a significant reduction of the production loss.49
Dutch data on the benefits of shelf-life extension are not
available yet, but it is clear that this will further increase
the CE of BCU. The cost of PRT PLTs originate primarily
from the cost of the PRT process and therefore it is possi-
ble to assess the effect of extending the PLT shelf life for
PRT PLTs. Our model indicates that a reduction of outdat-
ing from 20 percent to 5 percent will reduce the CE ratio
of PRT by 10 percent. This will not affect any of the con-
clusions drawn earlier.
In the Netherlands the vast majority (86%) of PLT
products are buffy coat–derived PLT pools.16 This situation
is different in the United States where the majority of PLT
products are apheresis products. If costs (and methods) of
PLT production in the United States would be comparable
to those in the Netherlands, then BCU would be cost-
effective only if the rate of sepsis through transfusion of
apheresis products would exceed 1 in 3000 transfusions.
As one of the reasons for applying apheresis in preparing
is the reduction of the contamination rate, this is not likely
to be the case.
The conclusion toward the CE of BCU is based on CE
criteria applied in general health care setting where pre-
vention or cure of disease is being judged. In case of treat-
ment of blood products, however, the setting is different
because these risks are iatrogenic. In the environmental
domain the Dutch government has maintained a risk pol-
icy since the 1980s that “no individual should be exposed
to an activity imposing a risk of dying greater than one in
a million (10−6) per year.”50 Although this standard is not
applicable to the safety of medical interventions nor to
blood products but for the general population, it does
explicitly quantify a negligible risk level for an individual.
It is clear that in the situation where no additional treat-
ment is applied the risk of death through bacterial con-
tamination will exceed this level, as the estimated
probability of death through bacterial sepsis after BCU
will be in the order of 10−5 per pooled PLT transfusion.
Whether the introduction of bacterial screening provides
a sufficient level of safety will depend on the safety level
that is considered appropriate and can only be demon-
strated if more insight into the incidence of transfusion-
related sepsis events is obtained by hemovigilance
programs. In case of treatment with PRT the required level
of safety could possibly be met irrespective the sepsis
incidence rate. Because no legislation with regard to
acceptable contamination levels or acceptable risk of
contaminations exists, here the dilemma between maxi-
mal (PRT) and optimal (BCU) risk reduction is at hand.
Further research and political guidance is required to back
up such decisions.
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